Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 12;185(10):1764-1776.e12.
doi: 10.1016/j.cell.2022.03.039. Epub 2022 Apr 25.

Targeted A-to-G base editing in human mitochondrial DNA with programmable deaminases

Affiliations
Free article

Targeted A-to-G base editing in human mitochondrial DNA with programmable deaminases

Sung-Ik Cho et al. Cell. .
Free article

Abstract

Mitochondrial DNA (mtDNA) editing paves the way for disease modeling of mitochondrial genetic disorders in cell lines and animals and also for the treatment of these diseases in the future. Bacterial cytidine deaminase DddA-derived cytosine base editors (DdCBEs) enabling mtDNA editing, however, are largely limited to C-to-T conversions in the 5'-TC context (e.g., TC-to-TT conversions), suitable for generating merely 1/8 of all possible transition (purine-to-purine and pyrimidine-to-pyrimidine) mutations. Here, we present transcription-activator-like effector (TALE)-linked deaminases (TALEDs), composed of custom-designed TALE DNA-binding arrays, a catalytically impaired, full-length DddA variant or split DddA originated from Burkholderia cenocepacia, and an engineered deoxyadenosine deaminase derived from the E. coli TadA protein, which induce targeted A-to-G editing in human mitochondria. Custom-designed TALEDs were highly efficient in human cells, catalyzing A-to-G conversions at a total of 17 target sites in various mitochondrial genes with editing frequencies of up to 49%.

Keywords: DNA; DddAtox; TALED; adenine deaminase; base editing; genome editing; mitochondria; organelle.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests S.-I.C., S.L., Y.G.M., K.L., J.M.L., E.C., and J.-S.K. have submitted a provisional patent application based on results reported in this paper. J.-S.K. is a founder of and shareholder in ToolGen. The other authors declare no competing interests.

Comment in

  • Prime time for base editing in the mitochondria.
    Morgan MA, Lange L, Schambach A. Morgan MA, et al. Signal Transduct Target Ther. 2022 Jul 6;7(1):213. doi: 10.1038/s41392-022-01068-x. Signal Transduct Target Ther. 2022. PMID: 35794105 Free PMC article. No abstract available.

Similar articles

Cited by

Publication types

LinkOut - more resources